< Return to Class Actions List
On December 20, 2004, Pfizer Inc. agreed to immediately discontinue advertising Celebrex after studies indicated an elevated risk of heart attacks, strokes and serious cardiovascular problems.
Health Canada has issued a warning that daily doses of 400 mg. and 800 mg. of Celebrex increases cardiovascular risks. It notes that a cancer prevention study by the National Cancer Institute in the United States showed increased risks for serious cardiovascular events. At the 400 mg. daily dose the risk was 2.5 times higher and at the 800 mg. daily dose the risk was 3.4 times higher.
Pfizer has stopped a trial it was sponsoring using a 400 mg. daily dose of Celebrex. Celebrex has been available in 100 mg., 200 mg. and 400 mg. doses.
More than 26 million people have taken Celebrex since was first approved by the U.S. Food and Drug Administration in December 1998.
Annual sales of Celebrex have exceeded $2 billion.
Like Vioxx, Celebrex is a COX-2 anti-inflammatory drug. In September 2004 Merck & Co. withdrew Vioxx from the market entirely.
McPhadden Samac Tuovi has commenced a class action against Pfizer Canada Inc. and Pfizer Inc. of the United States.
Attached is a copy of the issued Statement of Claim
If you or someone you know has suffered illness or death as result of using Celebrex you are invited to contact the law firm for a free assessment of your case. For your convenience, you may complete our free online Celebrex assessment and we will then begin assessing your ability to participate in the class action.
A tentative Settlement Agreement has been reached with Pfizer, the maker of Celebrex. The Settlement Agreement requries the approval of the Ontario Superior Court of Justice and the Superior Court of Quebec.
On November 30, 2011, the Honourable Mr. Justice Perell of the Ontario Superior Court of Justice approved the Settlement Agreement. Attached is a copy of his Reasons for Decision.
On January 9, 2012, the Honourable Mr. Justice Prevost of the Superior Court of Quebec approved the Settlement Agreement. Attached is a copy of his Reasons for Decision.
Bextra and Celebrex Class Action Settlement Update
This is an update regarding the ongoing administration of the settlement of the Bextra and Celebrex class action.
The settlement is administered by Collectiva Class Action Services based out of Montreal, QC.
Collectiva has advised us that, as of last month, it had received a total of 433 claims for compensation regarding personal injuries. All but 5 of those claims were then sent by Collectiva to the adjudicators, who are the medical doctors who decide whether a claim is eligible for compensation. Of the remaining 428 claims, 354 have already been adjudicated, meaning that the doctors have made a determination about whether those claims are eligible for compensation or not. The adjudicators were still reviewing 82 claims.
When an adjudicator makes a determination, Collectiva then delivers to the claimant, or to the law firm representing the claimant, a determination letter that describes and explains the adjudicator’s decision. If you have not yet received a determination letter, it is probably because the adjudicators are still considering your claim. If we are representing you in the settlement, then you should receive a determination letter from us within the next month or two.
Note that no settlement moneys will be distributed until every claim has been adjudicated. If the total value of all of the claims made exceeds the total amount contributed by the defendants, then every claim will be reduced on a pro rated basis.
Celebrex® is a registered trademark of Pfizer, Inc. and is used here only to identify the product in question.
< Return to Class Actions List